This round will be the 26th round (Round 26) of the application and selection process
(Outlines contraindications for niacin therapy, including active peptic ulcer disease, active liver disease with elevated enzymes, hypersensitivity to niacin, and arterial bleeding, as well as monitoring recommendations for blood pressure, glucose, uric acid, etc., due to niacins systemic effects)
(7)Fmoc-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val- (7) Preparation of Fmoc-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-resin: (6)Fmoc-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-1050530105010603DMF3DMF2DMFFmoc-Ala-OHDIEATBTU/HOBtHBTU/HOBtBOP/HOBt105010603DMF3DMF2Fmoc-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val- In the Fmoc-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-resin in step (6), add the decapping reagent at 10-50C for 5-30 minutes, dry it with a vacuum pump, and re-add the decapping reagent React the reagent at 10-50C for 10-60 minutes, drain it, wash it with isopropanol for 3 times, DMF for 3 times, and distilled DMF for 2 times, add Fmoc-Ala-OH, DIEA, TBTU dissolved in DMF /HOBt or HBTU/HOBt or BOP/HOBt mixture, react at 10-50C for 10-60 minutes, dry with a vacuum pump, wash 3 times with isopropanol, 3 times with DMF, 2 times with re-distilled DMF, Drain, obtain Fmoc-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-resin
Phase 2 data in patients with type 2 diabetes demonstrated HbA1c reductions of up to 2.16% at the 12mg dose after 36 weeks, along with 16.9% body weight reduction
